GlobeNewswire

WSO2 and Ping Identity Partner to Provide Comprehensive, AI-Powered Cyber-Attack Protection for APIs

Del

New open source extension integrates the AI-powered cybersecurity of PingIntelligence for APIs with the robust, policy-based security controls in WSO2 API Manager

Mountain View, CA and Denver, CO, June 10, 2019 (GLOBE NEWSWIRE) --

The proliferation of APIs catalyzed by digital transformation initiatives is viewed as a virtual goldmine by hackers, who are hijacking tokens, cookies and keys, as well as targeting weaknesses in individual APIs. And all too often, static security controls fail to stop these attacks. Now, WSO2 and Ping Identity have partnered to protect APIs against cyber-attacks by combining the artificial intelligence (AI) powered API cybersecurity of PingIntelligence for APIs with the robust policy-based controls in the open source WSO2 API Manager.

Through the partnership, WSO2 has developed an open source extension to communicate with the PingIntelligence API Security Enforcer (ASE) module, which can be deployed in the WSO2 API Gateway. As a result, WSO2 API Manager users can apply AI-based security analysis and threat blocking to their APIs along with static policy-based security controls.

Additionally, WSO2 and Ping Identity will co-host a webinar to discuss how enterprises can protect their API infrastructure from advanced attacks by leveraging the power of machine learning and AI in conjunction with API management. The event will be held on June 20, 2019 at 10:00 a.m. Pacific Daylight Time. To learn more and register, click here.

AI-Driven Security for API Management

“By 2022, API abuses will be the most-frequent attack vector resulting in data breaches for enterprise web applications,” observes Gartner in the report, How to Build an Effective API Security Strategy [1]. The report [2] further notes that, “A security strategy that manages access and protects systems from attack while still engaging digital ecosystems is essential to any API program.”

WSO2 API Manager, part of the WSO2 Integration Agile Platform, is the leading open source software for full API lifecycle management, monetization, and policy enforcement. Designed for deployment on-premises, in the cloud, as a managed cloud service, or in hybrid environments, WSO2 API Manager offers several policy-based options for security and access control. These include OAuth 2.0 authentication and authorization, API policy creation and enforcement, request and response validation, rate limiting, and the ability to set quotas, among others.

PingIntelligence for APIs is a leading solution for AI-powered API cybersecurity. By applying AI models to continuously inspect and report on all API activity, it automatically discovers anomalous API activity and threats across API infrastructures. Because bad actors are well versed in circumventing static security policies, PingIntelligence for APIs was purpose-built to recognize and stop emerging new threats that breach APIs while flying under the radar of foundational API security measures. The solution requires no policies or rules to be written, and it can recognize new and changing attacks.

Through the integrated functionality of PingIntelligence and WSO2 API Manager, organizations now have a complete solution for managing and protecting the APIs that drive their business. Examples of API attacks that can be reported and blocked using the integrated solution include attacks that use a valid user account to reverse engineer the API and breach other accounts to steal data—while looking like a normal user. Others include attacks that use stolen token, cookies, or API keys; attacks on login systems; remote application control; botnets scraping data; data exfiltration; API-specific denial of service/distributed denial of service (DoS/DDoS) attacks, as well as an array of attacks coming from authenticated users. To learn more and download the extension, visit https://wso2.com/ai-driven-security-enforcement-for-api-management.

“Ping Identity’s alliance with WSO2 extends our commitment to expanding our API security ecosystem,” said Bernard Harguindeguy, CTO, Ping Identity. “The advanced API security we deliver via PingIntelligence for APIs’ machine learning and artificial intelligence provides a strong complement to WSO2 API Manager in supporting the cybersecurity needs of today’s API-driven enterprises.”

“As more organizations implement internal and external API strategies to drive their digital transformation, APIs are becoming attractive targets for hackers,” said Paul Fremantle, WSO2 co-founder and CTO. “By integrating the extensive API management and control functionality of WSO2 API Manager with the AI-powered security of PingIntelligence for APIs, we can ensure that enterprises are well-equipped to detect and block attacks on their APIs—whether on-premises, across devices, or in the cloud.”

[1] Gartner, “How to Build an Effective API Security Strategy,” by Mark O'Neill, Dionisio Zumerle, Jeremy D'Hoinne, December 8, 2017.

[2] Gartner, “How to Build an Effective API Security Strategy” December 8, 2017.

About Ping Identity

Ping Identity envisions a digital world powered by intelligent identity. We help enterprises achieve Zero Trust identity-defined security and more personalized, streamlined user experiences. The Ping Intelligent Identity Platform provides customers, employees and partners with access to cloud, mobile, SaaS and on-premises applications and APIs, while also managing identity and profile data at scale. Over half of the Fortune 100 choose us for our identity expertise, open standards leadership, and partnership with companies including Microsoft, Amazon, and Google. We provide flexible options to extend hybrid IT environments and accelerate digital business initiatives with multi-factor authentication, single sign-on, access management, intelligent API security, directory, and data governance capabilities. Visit www.pingidentity.com.

About WSO2

WSO2 is the world’s #1 open source integration vendor, helping digital-driven organizations become integration agile. Customers choose us for our broad integrated platform, approach to open source, and agile transformation methodology. The company’s hybrid platform for developing, reusing, running and managing integrations prevents lock-in through open source software that runs on-premises or in the cloud. Today, hundreds of leading brands and thousands of global projects execute 6 trillion transactions annually using WSO2 integration technologies. Visit https://wso2.com to learn more.

Trademarks and registered trademarks are the properties of their respective owners.

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle

iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CESTPressemelding

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CESTPressemelding

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad

Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CESTPressemelding

Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi